Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).
Publication
, Conference
Wainberg, Z; Strickler, J; Gordon, M; Barve, M; Wang, L; Yue, H; Motwani, M; Kasichayanula, S; Naumovski, L; Hamilton, E
Published in: Ann Oncol
June 2018
Duke Scholars
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
June 2018
Volume
29 Suppl 5
Start / End Page
v66
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Wainberg, Z., Strickler, J., Gordon, M., Barve, M., Wang, L., Yue, H., … Hamilton, E. (2018). Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC). In Ann Oncol (Vol. 29 Suppl 5, p. v66). England. https://doi.org/10.1093/annonc/mdy151.233
Wainberg, Z., J. Strickler, M. Gordon, M. Barve, L. Wang, H. Yue, M. Motwani, S. Kasichayanula, L. Naumovski, and E. Hamilton. “Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).” In Ann Oncol, 29 Suppl 5:v66, 2018. https://doi.org/10.1093/annonc/mdy151.233.
Wainberg Z, Strickler J, Gordon M, Barve M, Wang L, Yue H, et al. Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC). In: Ann Oncol. 2018. p. v66.
Wainberg, Z., et al. “Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).” Ann Oncol, vol. 29 Suppl 5, 2018, p. v66. Pubmed, doi:10.1093/annonc/mdy151.233.
Wainberg Z, Strickler J, Gordon M, Barve M, Wang L, Yue H, Motwani M, Kasichayanula S, Naumovski L, Hamilton E. Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC). Ann Oncol. 2018. p. v66.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
June 2018
Volume
29 Suppl 5
Start / End Page
v66
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis